US2023381119A1PendingUtilityA1
Use of histone acetyltransferase inhibitor amidoximes as anti-proliferative agents
Est. expiryOct 2, 2037(~11.2 yrs left)· nominal 20-yr term from priority
A61K 31/155A61K 33/24A61K 45/06A61P 35/00A61K 31/15
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Described herein is the use of bisamidoximes compounds for the treatment of HAT malfunction related pathologies.
Claims
exact text as granted — not AI-modified1 - 7 . (canceled)
8 . A pharmaceutical composition comprising one or more bisamidoximes, wherein the one or more bisamidoximes are selected from the group of compounds consisting of JJMB 5, JJMB6, and JJMB 9:
9 . The pharmaceutical composition of claim 8 , comprising two or more bisamidoximes.
10 . The pharmaceutical composition of claim 8 , comprising JJMB5 and JJMB 9.
11 . The pharmaceutical composition of claim 8 , comprising JJMB5.
12 . The pharmaceutical composition of claim 8 , comprising JJMB6.
13 . The pharmaceutical composition of claim 8 , comprising JJMB 9.
14 . The pharmaceutical composition of claim 8 , further comprising an anticancer agent.
15 . The pharmaceutical composition of claim 14 , wherein the anticancer agent is cisplatin.
16 . The pharmaceutical composition of claim 8 being a therapeutically effective amount for inhibiting histone acetyltransferases (HATs) in a HAT malfunction related pathology.
17 . The pharmaceutical composition of claim 8 being a therapeutically effective amount for treating colon cancer, breast cancer, or lung cancer in a subject.
18 . A pharmaceutical composition comprising one or more bisamidoximes, wherein the one or more bisamidoximes are selected from the group of compounds consisting of JJMB 5, JJMB6, JJMB 7, and JJMB 9:
19 . The pharmaceutical composition of claim 18 , comprising two or more bisamidoximes.
20 . The pharmaceutical composition of claim 18 , comprising JJMB5 and JJMB 9.
21 . The pharmaceutical composition of claim 18 , comprising JJMB5 and JJMB7.
22 . The pharmaceutical composition of claim 18 , comprising JJMB7 and JJMB 9.
23 . The pharmaceutical composition of claim 18 , comprising JJMB 7.
24 . The pharmaceutical composition of claim 18 , further comprising an anticancer agent.
25 . The pharmaceutical composition of claim 24 , wherein the anticancer agent is cisplatin.
26 . The pharmaceutical composition of claim 18 being a therapeutically effective amount for inhibiting histone acetyltransferases (HATs) in a HAT malfunction related pathology.
27 . The pharmaceutical composition of claim 18 being a therapeutically effective amount for treating colon cancer, breast cancer, or lung cancer in a subject.Join the waitlist — get patent alerts
Track US2023381119A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.